| Literature DB >> 26839480 |
Cheol-Kyu Park1, Hong-Joon Shin1, Yu-Il Kim1, Sung-Chul Lim1, Jeong-Sun Yoon1, Young-Su Kim1, Jung-Chul Kim2, Yong-Soo Kwon1.
Abstract
Default from tuberculosis (TB) treatment could exacerbate the disease and result in the emergence of drug resistance. This study identified the risk factors for default from TB treatment in Korea. This single-center case-control study analyzed 46 default cases and 100 controls. Default was defined as interrupting treatment for 2 or more consecutive months. The reasons for default were mainly incorrect perception or information about TB (41.3%) and experience of adverse events due to TB drugs (41.3%). In univariate analysis, low income (< 2,000 US dollars/month, 88.1% vs. 68.4%, P = 0.015), absence of TB stigma (4.3% vs. 61.3%, P < 0.001), treatment by a non-pulmonologist (74.1% vs. 25.9%, P < 0.001), history of previous treatment (37.0% vs. 19.0%, P = 0.019), former defaulter (15.2% vs. 2.0%, P = 0.005), and combined extrapulmonary TB (54.3% vs. 34.0%, P = 0.020) were significant risk factors for default. In multivariate analysis, the absence of TB stigma (adjusted odd ratio [aOR]: 46.299, 95% confidence interval [CI]: 8.078-265.365, P < 0.001), treatment by a non-pulmonologist (aOR: 14.567, 95% CI: 3.260-65.089, P < 0.001), former defaulters (aOR: 33.226, 95% CI: 2.658-415.309, P = 0.007), and low income (aOR: 5.246, 95% CI: 1.249-22.029, P = 0.024) were independent predictors of default from TB treatment. In conclusion, patients with absence of disease stigma, treated by a non-pulmonologist, who were former defaulters, and with low income should be carefully monitored during TB treatment in Korea to avoid treatment default.Entities:
Keywords: Chemotherapy; Lost to Follow up; Risk Factors; Tuberculosis
Mesh:
Substances:
Year: 2016 PMID: 26839480 PMCID: PMC4729506 DOI: 10.3346/jkms.2016.31.2.254
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Sociodemographic characteristics of the control and default groups
| Characteristics | Total | Control | Default | |
|---|---|---|---|---|
| Age, yr | 52.5 (31.0-70.0) | 53.5 (31.0-70.5) | 52.0 (30.0-69.0) | 0.745 |
| Sex | 0.643 | |||
| Female | 58 (39.7) | 41 (41.0) | 17 (37.0) | |
| Male | 88 (60.3) | 59 (59.0) | 29 (63.0) | |
| BMI, kg/m2 | 21.0 (19.5-23.2) | 20.4 (19.2-22.3) | 21.9 (20.3-24.5) | 0.062 |
| < 18.5 | 17 (11.6) | 15 (15.0) | 2 (4.3) | |
| ≥ 18.5 | 130 (88.4) | 85 (85.0) | 44 (95.7) | |
| Smoking | 0.086 | |||
| Never smoker | 66 (45.2) | 50 (50.0) | 16 (34.8) | |
| Ever smoker | 80 (54.8) | 50 (50.0) | 30 (65.2) | |
| Alcohol consumption | 0.219 | |||
| No | 90 (61.6) | 65 (65.0) | 25 (54.3) | |
| Yes | 56 (38.4) | 35 (35.0) | 21 (45.7) | |
| Herbal medication | 9 (6.2) | 6 (6.0) | 3 (6.5) | 1.000 |
| Employment | 0.245 | |||
| Regular | 69 (47.3) | 44 (44.0) | 25 (54.3) | |
| Irregular or unemployed | 77 (52.7) | 56 (56.0) | 21 (45.7) | |
| Marriage | 0.640 | |||
| Married | 96 (65.8) | 67 (67.0) | 29 (63.0) | |
| Single/divorced/bereaved | 50 (34.2) | 33 (33.0) | 17 (37.0) | |
| Family members | 0.951 | |||
| Living together | 117 (80.1) | 80 (80.0) | 37 (80.4) | |
| Living alone | 29 (19.9) | 20 (20.0) | 9 (19.6) | |
| Education | 144 | 98 | 46 | 0.673 |
| Primary | 45 (31.3) | 32 (32.7) | 13 (28.3) | |
| Secondary | 20 (13.9) | 12 (12.2) | 8 (17.4) | |
| Post-secondary | 79 (54.9) | 54 (55.1) | 25 (54.3) | |
| Income/month | 137 | 95 | 42 | 0.015 |
| < 2,000 US dollars | 102 (74.5) | 65 (68.4) | 37 (88.1) | |
| ≥ 2,000 US dollars | 35 (25.5) | 30 (31.6) | 5 (11.9) | |
| Insurance | 0.549 | |||
| National health insurance | 132 (90.4) | 89 (89.0) | 43 (93.5) | |
| Public assistance | 14 (9.6) | 11 (11.0) | 3 (6.5) | |
| Distance from home to clinic, km | 24.3 (7.6-85.3) | 25.2 (11.2-88.0) | 20.4 (6.5-75.3) | 0.190 |
| < 50 | 85 (58.2) | 57 (57.0) | 28 (60.9) | 0.258 |
| 50-100 | 38 (26.0) | 24 (24.0) | 14 (30.4) | |
| > 100 | 23 (15.8) | 19 (19.0) | 4 (8.7) |
Values are expressed as median (interquartile range) or number of patients (%). BMI, Body mass index.
Clinical and microbiologic characteristics of the control and default groups
| Parameters | Total | Control | Default | |
|---|---|---|---|---|
| Attending physician | < 0.001 | |||
| Non-pulmonologist | 27 (18.5) | 7 (7.0) | 20 (43.5) | |
| Pulmonologist | 119 (81.5) | 93 (93.0) | 26 (56.5) | |
| Underlying diseases | ||||
| Diabetes | 21 (14.4) | 12 (12.0) | 9 (19.6) | 0.226 |
| Chronic liver disease | 17 (11.6) | 12 (12.0) | 5 (10.9) | 0.843 |
| Chronic cardiac disease | 27 (18.5) | 17 (17.0) | 10 (21.7) | 0.493 |
| Chronic kidney disease | 3 (2.1) | 2 (2.0) | 1 (2.2) | 1.000 |
| Cerebrovascular disease | 10 (6.8) | 6 (6.0) | 4 (8.7) | 0.725 |
| Malignancy | 8 (5.5) | 5 (5.0) | 3 (6.5) | 0.707 |
| Chronic pulmonary disease | 10 (6.8) | 5 (5.0) | 5 (10.9) | 0.288 |
| Psychological disorder | 2 (1.4) | 1 (1.0) | 1 (2.2) | 0.532 |
| Previous treatment | 36 (24.7) | 19 (19.0) | 17 (37.0) | 0.019 |
| Number of treatments | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) | 0.071 |
| Duration, months | 6.0 (3.5-8.5) | 6.0 (5.0-9.5) | 6.0 (2.0-8.0) | 0.126 |
| Former defaulter | 9 (6.2) | 2 (2.0) | 7 (15.2) | 0.005 |
| EPTB | ||||
| Combined | 59 (40.4) | 34 (34.0) | 25 (54.3) | 0.020 |
| Alone | 25 (17.1) | 6 (6.0) | 19 (41.3) | < 0.001 |
| Radiologic findings | 145 | 100 | 45 | |
| Cavity | 28 (19.3) | 19 (19.0) | 9 (20.0) | 0.888 |
| Extent | 123 | 94 | 29 | 0.559 |
| Localized | 90 (73.2) | 70 (74.5) | 20 (69.0) | |
| Bilateral disease | 33 (26.8) | 24 (25.5) | 9 (31.0) | |
| AFB smear | 137 | 100 | 37 | 0.163 |
| Positive | 42 (30.7) | 34 (34.0) | 8 (21.6) | |
| Negative | 95 (69.3) | 66 (66.0) | 29 (78.4) | |
| AFB culture | 134 | 96 | 38 | 0.085 |
| Positive | 89 (66.4) | 68 (70.8) | 21 (55.3) | |
| Negative | 45 (33.6) | 28 (29.2) | 17 (44.7) |
Values are expressed as median (interquartile range) or number of patients (%). AFB, acid-fast bacilli; EPTB, extrapulmonary tuberculosis.
Drug resistance, therapeutic characteristics, adverse drug reactions, and perceptions of disease in the control and default groups
| Variables | Total | Control | Default | |
|---|---|---|---|---|
| Resistance | 90 | 75 | 15 | |
| Susceptible | 71 (78.9) | 58 (77.3) | 13 (86.7) | 1.000 |
| Non-MDR drug resistance | 9 (10.0) | 8 (10.7) | 1 (6.7) | |
| MDR | 10 (11.1) | 9 (12.0) | 1 (6.7) | |
| Admission during intensive treatment phase | 70 (47.9) | 52 (52.0) | 18 (39.1) | 0.148 |
| Regimen | 0.371 | |||
| With pyrazinamide | 132 (90.4) | 92 (92.0) | 40 (87.0) | |
| Without pyrazinamide | 14 (9.6) | 8 (8.0) | 6 (13.0) | |
| Improvement of symptoms after treatment | 137 | 98 | 39 | |
| Improved | 96 (70.1) | 71 (72.4) | 25 (64.1) | 0.336 |
| Not improved | 41 (29.9) | 27 (27.6) | 14 (35.9) | |
| Adverse drug reactions | 144 | 100 | 44 | |
| Present | 82 (56.9) | 58 (58.0) | 24 (54.5) | 0.700 |
| Gastrointestinal | 39 (27.3) | 28 (28.0) | 11 (25.0) | 0.766 |
| Liver | 19 (13.2) | 13 (13.0) | 6 (13.6) | 0.917 |
| Skin | 41 (28.5) | 30 (30.0) | 11 (25.0) | 0.540 |
| Optic | 8 (5.6) | 8 (8.0) | 0 (0.0) | 0.106 |
| Joint | 9 (6.3) | 7 (7.0) | 2 (4.5) | 0.722 |
| Drug fever | 5 (3.5) | 2 (2.0) | 3 (6.8) | 0.167 |
| Peripheral neuropathy | 9 (6.3) | 7 (7.0) | 2 (4.5) | 0.722 |
| Others* | 7 (4.9) | 6 (6.0) | 1 (2.3) | |
| Disease perception | 139 | 93 | 46 | |
| Disease stigma | 59 (42.4) | 57 (61.3) | 2 (4.3) | < 0.001 |
| Incorrect perception or information | 61 (43.9) | 42 (45.2) | 19 (41.3) | 0.666 |
Values are expressed as median (interquartile range) or number of patients (%). MDR, multidrug resistant.
*Includes headache (n = 3), dizziness (n = 2), tinnitus (n = 1), and cytopenia (n = 1).